RBC Raises Price Target for Vertex Pharmaceuticals Amid Biotech Sector Outlook Update
RBC Capital Markets increased its price target for Vertex Pharmaceuticals (VRTX) from $541 to $543, maintaining an Outperform rating. The update comes ahead of first-quarter earnings and amid broader biotech sector considerations, including seasonal challenges and potential M&A activity. Vertex also received expanded FDA approval for its cystic fibrosis treatments.
Tickers: $VRTX
Topics: ALYFTREK Biotech Sector Outlook Cystic Fibrosis FDA Approval Price Target Update TRIKAFTA Vertex Pharmaceuticals